Last reviewed · How we verify
Adapt Produtos Oftalmológicos Ltda. — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
2 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| moxifloxacin/prednisolone combination | moxifloxacin/prednisolone combination | phase 3 | Fluoroquinolone antibiotic and corticosteroid combination | DNA gyrase and topoisomerase IV (moxifloxacin), phospholipase A2 and other enzymes (prednisolone) | Ophthalmology | |
| moxifloxacin 0,5% + prednisolone 1% | moxifloxacin 0,5% + prednisolone 1% | phase 3 | fluoroquinolone antibiotic and corticosteroid | DNA gyrase and topoisomerase IV, phospholipase A2 | Ophthalmology |
Therapeutic area mix
- Ophthalmology · 2
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
Subscribe to ongoing alerts
Every new pipeline event for Adapt Produtos Oftalmológicos Ltda.:
- Adapt Produtos Oftalmológicos Ltda. pipeline updates — RSS
- Adapt Produtos Oftalmológicos Ltda. pipeline updates — Atom
- Adapt Produtos Oftalmológicos Ltda. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Adapt Produtos Oftalmológicos Ltda. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/adapt-produtos-oftalmol-gicos-ltda. Accessed 2026-05-16.